3//SEC Filing
Poseidon Bio, LLC 3
Accession 0001493152-23-005362
CIK 0001836612other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 9:40 PM ET
Size
22.7 KB
Accession
0001493152-23-005362
Insider Transaction Report
Form 3
Poseidon Bio, LLC
10% Owner
Holdings
- 22,842,756
Class A Common Stock, par value $0.0001
Earnout Rights
Exp: 2026-02-14→ Class A Common Stock (18,582,930 underlying)
Footnotes (4)
- [F1]An Agreement and Plan of Merger was entered into on August 31, 2022 and amended on December 5, 2022 (as amended, the "Business Combination Agreement"; such transactions contemplated thereby, collectively, the "Business Combination") between Ocean Biomedical Holdings, Inc., formerly known as Ocean Biomedical, Inc. ("Legacy Ocean"), Aesther Healthcare Acquisition Corp. ("AHAC"), AHAC Merger Sub, Inc. ("Merger Sub"), and certain other parties thereto. In accordance with the Business Combination Agreement, on February 14, 2023 (the "Closing Date"), (i) Merger Sub merged with and into Legacy Ocean (such transaction, the "Merger"), (ii) Legacy Ocean continued as the surviving entity of the Merger and a wholly-owned subsidiary of AHAC, and (iii) AHAC changed its name to Ocean Biomedical, Inc. (such post-Business Combination entity, the "Issuer"). Capitalized terms that are used but not defined in this Form 3 have the meanings given to them in the Business Combination Agreement.
- [F2]Poseidon Bio, LLC ("Poseidon") acquired these shares of the Issuer's Class A Common Stock, par value $0.0001 per share, as consideration for Poseidon's Legacy Ocean common stock, which AHAC acquired in the Merger on the Closing Date.
- [F3]As additional Merger consideration, the former Legacy Ocean stockholders (the "Pre-Merger Stockholders") have the contingent right (the "Earnout Right") to receive up to an aggregate maximum of 19,000,000 shares of the Issuer's common stock (the "Earnout Shares"), issued in three Earnout Share Payments, if, for 20 out of any 30 consecutive trading days during the period from the Closing Date until the 36-month anniversary thereof (the "Earnout Period"), the Issuer's VWAP equals or exceeds: (i) $15.00 per share, in which case each Pre-Merger Stockholder will be issued its Pro Rata Share of 5,000,000 Earnout Shares (the "First Earnout Share Payment"); (ii) $17.50 per share, in which case each Pre-Merger Stockholder will be issued its Pro Rata Share of 7,000,000 Earnout Shares (the "Second Earnout Share Payment"); and (iii) $20.00 per share, in which case each Pre-Merger Stockholder will be issued its Pro Rata Share of 7,000,000 Earnout Shares (the "Third Earnout Share Payment").
- [F4]On the Closing Date of the Merger, Poseidon received the Earnout Right to acquire its Pro Rata Share of the aggregate maximum of 19,000,000 Earnout Shares that are issuable on a contingent basis to the Pre-Merger Stockholders under the Business Combination Agreement, which entitles Poseidon to receive up to 18,582,930 Earnout Shares, (i) 4,890,245 of which will be issued in connection with the First Earnout Share Payment, (ii) 6,846,343 of which will be issued in connection with the Second Earnout Share Payment, and (iii) 6,846,343 of which will be issued in connection with the Third Earnout Share Payment, with each Earnout Share Payment contingent on the Issuer's VWAP equaling or exceeding the required Share Price Target for 20 out of any 30 consecutive trading days during the Earnout Period. Poseidon's right to receive Earnout Shares pursuant to the Earnout Right granted in the Business Combination Agreement became fixed and irrevocable on the Closing Date of the Merger.
Documents
Issuer
Ocean Biomedical Holdings, Inc.
CIK 0001836612
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001874219
Filing Metadata
- Form type
- 3
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 9:40 PM ET
- Size
- 22.7 KB